Celsion Co. (NASDAQ:CLSN) Chairman Michael H. Tardugno acquired 5,000 shares of Celsion stock in a transaction on Thursday, May 16th. The shares were bought at an average cost of $2.16 per share, with a total value of $10,800.00. Following the completion of the transaction, the chairman now owns 32,700 shares of the company’s stock, valued at $70,632. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.
Shares of Celsion stock traded down $0.01 during trading on Friday, reaching $2.14. The company’s stock had a trading volume of 85,556 shares, compared to its average volume of 145,028. The stock has a market cap of $41.86 million, a PE ratio of -3.15 and a beta of 2.20. Celsion Co. has a 52 week low of $1.35 and a 52 week high of $3.48. The company has a debt-to-equity ratio of 0.45, a quick ratio of 4.61 and a current ratio of 4.61.
Celsion (NASDAQ:CLSN) last announced its earnings results on Wednesday, May 15th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.01). The business had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.13 million. Celsion had a negative net margin of 1,954.60% and a negative return on equity of 68.04%. Equities research analysts predict that Celsion Co. will post -0.89 earnings per share for the current fiscal year.
Several institutional investors have recently made changes to their positions in CLSN. Vanguard Group Inc boosted its position in shares of Celsion by 40.9% in the third quarter. Vanguard Group Inc now owns 740,132 shares of the biotechnology company’s stock valued at $2,050,000 after acquiring an additional 214,829 shares during the period. Vanguard Group Inc. boosted its position in shares of Celsion by 40.9% in the third quarter. Vanguard Group Inc. now owns 740,132 shares of the biotechnology company’s stock valued at $2,050,000 after acquiring an additional 214,829 shares during the period. BlackRock Inc. boosted its position in shares of Celsion by 21.9% in the fourth quarter. BlackRock Inc. now owns 142,426 shares of the biotechnology company’s stock valued at $202,000 after acquiring an additional 25,548 shares during the period. Finally, Northern Trust Corp boosted its position in shares of Celsion by 22.2% in the first quarter. Northern Trust Corp now owns 34,725 shares of the biotechnology company’s stock valued at $68,000 after acquiring an additional 6,306 shares during the period. 5.49% of the stock is owned by institutional investors.
Celsion Company Profile
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.
Further Reading: Oversold
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.